21 May 2021 - Vericiguat is being considered for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.

The CHMP of the EMA has recommended vericiguat, a soluble guanylate cyclase stimulator, for marketing authorisation in the European Union. 

Once approved, the use of vericiguat (2.5 mg, 5 mg, and 10 mg) will be authorised for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.

Read Bayer press release